Accueil・Liste d'Actions・Roivant Sciences Ltd

Roivant Sciences Ltd

Fermé

SecteurSoins de santé

36.32 3.95

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

35.99

Max

36.43

Chiffres clés
By Trading Economics
Revenu	669M 356M
Ventes	521K 2.5M
Marge bénéficiaire	14,116.825
Employés	721
EBITDA	744M 455M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+14.01% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	3.9B 24B
Ouverture précédente	32.37
Clôture précédente	36.32

Sentiment de l'Actualité

By Acuity

12%

88%

14 / 340 Classement par Healthcare

Roivant Sciences Ltd Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 août 2026, 20:02 UTC

Event

News

Roivant Sciences Ltd shares are higher as HC Wainwright maintains a Buy rating and raises the price target to $41 amid positive developments in its product pipeline.

6 août 2026, 20:03 UTC

News

Event

Roivant Sciences reported a net loss of $290.6 million in Q1, exceeding expectations. Shares are higher despite pulling back from session highs earlier.

5 août 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Wednesday's close. The stock is positioned above its 20-day moving average.

4 août 2026, 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

3 août 2026, 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

31 juil. 2026, 20:02 UTC

Roivant Sciences Ltd shares are lower today amid significant declines in biotechnology stocks, breaking a trend of higher daily closes since Thursday.

30 juil. 2026, 23:46 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting a modest gain since Thursday's close. The stock fluctuated within a narrow range.

29 juil. 2026, 23:02 UTC

Roivant Sciences Ltd shares are lower in after-market hours amid broader market concerns and unusual volatility, with no specific company news identified.

28 juil. 2026, 23:06 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing a trend of declines over the past three sessions without any specific news to explain the movement.

24 juil. 2026, 18:46 UTC

Roivant Sciences Ltd shares are trading higher, reflecting broader market dynamics amid a rebound in some sectors following a significant decline in oil prices.

23 juil. 2026, 20:06 UTC

Roivant Sciences Ltd is higher during Thursday's session, despite pulling back from an earlier session high. No specific news was identified for the movement.

22 juil. 2026, 22:26 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market volatility.

21 juil. 2026, 22:21 UTC

Roivant Sciences Ltd shares are lower in after-market hours, despite a broader market rebound following positive earnings from companies like General Motors and 3M.

20 juil. 2026, 16:36 UTC

Roivant Sciences Ltd. shares are lower today amid ongoing Middle East conflict affecting market sentiment and fluctuations in Brent crude prices.

Comparaison

Variation de prix

Roivant Sciences Ltd prévision

Objectif de Prix

By TipRanks

14.01% hausse

Prévisions sur 12 Mois

Moyen 41.43 USD 14.01%

Haut 50 USD

Bas 35 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

14 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.